JUNS · Jupiter Neurosciences, Inc. · Financials
$3.05
-0.10 (-3.17%)
At close · Sep 11
Going-concern doubt
— flagged Aug 14, 2026
Substantial doubt about the company's ability to continue as a going concern.
“Our management has concluded that our historical recurring losses from operations and negative cash flows from operations as well as our dependence on private equity and other financings raise substantial doubt about our ability to continue as a going concern and our auditor has included an explanatory paragraph relating to our ability to continue as a going concern in its audit report for the fiscal years ended December 31, 2025 and 2024.”View the 10-Q filed Aug 14, 2026
Market Cap
$2.35M
Shares
770,081
Income-statement, balance-sheet and cash-flow figures from SEC filings, plus a debt profile anchored in the latest 10-K and updated by each 10-Q and debt exhibit.
Revenue
$21.8K
FY2025
Net Income
-$8.64M
-254.4%
FY2025
Gross Margin
80.59%
FY2025
Operating Margin
-40873.19%
FY2025
Diluted EPS
-$18.75
-212.5%
FY2025
Operating Cash Flow
-$5.41M
-38.4%
FY2025
Chart any reported metric, KPI or segment over time — the full statement history lives here
Search above to add metrics — fundamentals, product and segment revenue, company KPIs, valuation.
| Line Item | TTM | FY2025 | FY2024 | FY2023 |
|---|---|---|---|---|
| — | $21.8K | $0 | — | |
| — | $4231 | — | — | |
| — | $17.57K | — | — | |
| — | 80.59% | — | — | |
| $1.87M | $2.09M | $492.66K | $954.79K | |
| $7.99M | $6.84M | $2.6M | $2.92M | |
| — | $6.84M | — | — | |
| $9.86M | $8.93M | $3.09M | $3.87M | |
| -$9.81M | -$8.91M | -$3.09M | -$3.87M | |
| — | -40873.19% | — | — | |
| $272.92K | $66.02K | $248.37K | $218.71K | |
| — | — | $5557 | $482 | |
| $612.36K | $263.82K | $651.66K | -$912.92K | |
| -$9.2M | -$8.64M | -$2.44M | -$4.78M | |
| — | -39662.77% | — | — | |
| USD/shares | -$18.49 | -$18.75 | -$6.00 | -$13.50 |
| USD/shares | -$18.49 | -$18.75 | -$6.00 | -$13.50 |
| shares | — | 461.71K | 383.77K | 352.07K |
| shares | — | 461.71K | 383.77K | 352.07K |
Italic rows are computed from reported lines — open a row's info icon for its formula. Values reflect the latest filing (restatements included); per-share figures on today's split basis. Click a value for its source filing.
TTM: trailing twelve months through the latest reported quarter — flows sum the last four quarters, balances take the latest.
Debt Profile
Annual debt figures are established from 10-K filings and updated by subsequent 10-Q and 8-K disclosures. Instrument balances are not summed into a company total unless the filing itself reports that total.
Debt data is being processed. Please check back later.
Price & Valuation
Multiples computed on the strict TTM/EV methodology — today's snapshot against peers, and each ratio recomputed as of past filing dates.
Valuation
EV/Revenue
—
Peer median 1.90×
EV/EBIT
—
P/E (TTM)
—
Peer medians compare against the 130 similar-size Biotechnology companies (of 536 listed).